

available at [www.sciencedirect.com](http://www.sciencedirect.com)journal homepage: [www.elsevier.com/locate/dnarepair](http://www.elsevier.com/locate/dnarepair)

# Reduced efficiency and increased mutagenicity of translesion DNA synthesis across a TT cyclobutane pyrimidine dimer, but not a TT 6-4 photoproduct, in human cells lacking DNA polymerase $\eta$

Ayal Hendel<sup>a,1</sup>, Omer Ziv<sup>a,1</sup>, Quentin Gueranger<sup>b</sup>, Nicholas Geacintov<sup>c</sup>, Zvi Livneh<sup>a,\*,2</sup>

<sup>a</sup> Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel

<sup>b</sup> INSERM U783, Université Paris Descartes, Faculté Necker, 156 rue de Vaugirard, 75015 Paris, France

<sup>c</sup> Chemistry Department, New York University, New York, NY 10003-5180, USA

## ARTICLE INFO

### Article history:

Received 2 March 2008

Received in revised form 5 June 2008

Accepted 12 June 2008

Published on line 3 August 2008

### Keywords:

DNA repair  
UV carcinogenesis  
Skin cancer  
Mutagenesis  
Error-prone repair

## ABSTRACT

Xeroderma pigmentosum variant (XPV) patients carry germ-line mutations in DNA polymerase  $\eta$  ( $\text{pol}\eta$ ), a major translesion DNA synthesis (TLS) polymerase, and exhibit severe sunlight sensitivity and high predisposition to skin cancer. Using a quantitative TLS assay system based on gapped plasmids we analyzed TLS across a site-specific TT CPD (thymine–thymine cyclobutane pyrimidine dimer) or TT 6-4 PP (thymine–thymine 6-4 photoproduct) in three pairs of  $\text{pol}\eta$ -proficient and deficient human cells. TLS across the TT CPD lesion was reduced by 2.6–4.4-fold in cells lacking  $\text{pol}\eta$ , and exhibited a strong 6–17-fold increase in mutation frequency at the TT CPD. All targeted mutations (74%) in  $\text{pol}\eta$ -deficient cells were opposite the 3'T of the CPD, however, a significant fraction (23%) were semi-targeted to the nearest nucleotides flanking the CPD. Deletions and insertions were observed at a low frequency, which increased in the absence of  $\text{pol}\eta$ , consistent with the formation of double strand breaks due to defective TLS. TLS across TT 6-4 PP was about twofold lower than across CPD, and was marginally reduced in  $\text{pol}\eta$ -deficient cells. TLS across TT 6-4 PP was highly mutagenic (27–63%), with multiple mutations types, and no significant difference between cells with or without  $\text{pol}\eta$ . Approximately 50% of the mutations formed were semi-targeted, of which 84–93% were due to the insertion of an A opposite the template G 5' to the 6-4 PP. These results, which are consistent with the UV hyper-mutability of XPV cells, highlight the critical role of  $\text{pol}\eta$  in error-free TLS across CPD in human cells, and suggest a potential involvement, although minor, of  $\text{pol}\eta$  in TLS across 6-4 PP under some conditions.

© 2008 Elsevier B.V. All rights reserved.

## 1. Introduction

UV light is an established mutagen and carcinogen in humans, and deficiencies in the ability to repair or tolerate UV lesions

cause the severe hereditary disease xeroderma pigmentosum (XP), characterized by extreme sunlight sensitivity and high predisposition to skin cancer [1]. The two major biologically significant UV lesions are the cyclobutane pyrimidine dimers

\* Corresponding author. Tel.: +972 8 934 3203; fax: +972 8 934 4169.

E-mail address: [zvi.livneh@weizmann.ac.il](mailto:zvi.livneh@weizmann.ac.il) (Z. Livneh).

<sup>1</sup> These authors have equally contributed to this work.

<sup>2</sup> Incumbent of The Maxwell Ellis Professorial Chair in Biomedical Research.

1568-7864/\$ – see front matter © 2008 Elsevier B.V. All rights reserved.

doi:10.1016/j.dnarep.2008.06.008

(CPD), and the 6-4 photoproducts (6-4 PP). While 6-4 PP are primarily repaired by error-free nucleotide excision repair (NER), CPD are weak substrates for NER, and therefore frequently escape error-free repair [2–4]. During replication CPD are tolerated by translesion DNA synthesis (TLS), which is carried out by DNA polymerase  $\eta$  ( $\text{pol}\eta$ ) with relatively high fidelity. This conclusion is based on the biochemical properties of purified  $\text{pol}\eta$  [5,6], and on the UV hyper-mutability of cells from patients with the variant form of XP (XPV) [7]. In these patients the lack of  $\text{pol}\eta$  activity causes clinical symptoms similar to the NER-deficient forms of XP, including high predisposition to skin cancer [1,8]. The slight UV sensitivity and the UV hyper-mutability of cells from XPV patients are generally explained by the activity of an alternative TLS DNA polymerase, most likely  $\text{pol}\iota$ , which bypasses the CPD with lower efficiency and higher error frequency compared to  $\text{pol}\eta$  [9–13], leading to increased sensitivity and hyper-mutability, respectively. Although cells from XPV patients were extensively investigated, to date the direct effects of the lack of  $\text{pol}\eta$  on TLS across defined CPD and 6-4 PP in cells was not determined. Here we present a quantitative analysis of TLS across site-specific TT CPD and TT 6-4 PP lesions using a TLS assay system based on transfection of cultured cells with gapped plasmids. This was done in three different pairs of  $\text{pol}\eta$ -proficient and  $\text{pol}\eta$ -deficient human cells, and included DNA sequence analysis of over a 1000 unselected TLS events. Our results show, for the first time, that TLS across a TT CPD in XPV  $\text{pol}\eta$ -deficient cells is less efficient and more mutagenic than in  $\text{pol}\eta$ -proficient cells, and it exhibits a typical mutational signature. In contrast, TLS across a TT 6-4 PP is hardly affected by the absence of  $\text{pol}\eta$ .

## 2. Materials and methods

### 2.1. Materials

Dulbecco's phosphate buffered saline (PBS) without calcium chloride and magnesium chloride, and minimum essential medium (MEM) Eagle were from Sigma. Roswell Park Memorial Institute medium (RPMI 1640) with 2 mM L-glutamine was from GIBCO/BRL. Trypsin-EDTA, 100 mM glutamine, and a mixture of penicillin and streptomycin for cell culture were from Biological Industries (Beit Haemek, Israel). Fetal bovine serum (FBS) was from HyClone. JetPEI was from Polyplus-transfection (Illkirch, France).

### 2.2. Cell cultures

GM00495 (normal) and GM03055 (XPV) human fibroblasts were purchased from Corriell cell repository. The SV40-transformed human fibroblasts, MRC5 (normal) and XP30RO (sv) (XPV; also designated GM3617 were gifts from A.R. Lehmann (University of Sussex, Brighton, UK). The human fibroblast cells were cultured in MEM supplemented with 2 mM L-glutamine, 100 units/ml of penicillin, 100  $\mu\text{g}/\text{ml}$  of streptomycin, and 15% FBS. The  $\text{pol}\eta$ -null derivative of the type I Burkitt's lymphoma BL2 cell lines was obtained by gene-targeted inactivation as described [14]. The lymphoma cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine, 100 units/ml of peni-

cillin, 100  $\mu\text{g}/\text{ml}$  of streptomycin, and 10% FBS. The cells were incubated at 37 °C in a 5%  $\text{CO}_2$  atmosphere.

### 2.3. Construction of DNA substrates and plasmids

DNA oligonucleotides without a lesion were supplied by Sigma-Genosys. The construction of the control gapped plasmid GP20 was previously described [15]. A gap-lesion plasmid with a site-specific TT CPD was prepared using the site-specifically modified 11-mer oligonucleotide 5'-GCAAGTTTGAG-3' containing a single site-specific TT CPD (underlined) that was generated as previously described [16]. It was extended to a 53-mer oligonucleotide by ligating to its 5' end the 21-mer 5'-ACCGCAACGAAAGTGATTCCTC-3', and to its 3' end the 21-mer 5'-CTGGCTACTTGAACCAGACCG-3', using as a scaffold the 33-mer 5'-AAGTAGCCAGCTCCAACCTGCGAGGAATCACTT-3'. The resulting 53-mer was separated from the scaffold and excess 21-mer on a 12% denaturing polyacrylamide gel containing 8 M urea, and used to construct the gap-lesion plasmid GP-TT-CPD. A gap-lesion plasmid with a site-specific TT 6-4 PP was prepared using the site-specifically modified 11-mer oligonucleotide 5'-GCAAGTTTGAG-3' containing a single site-specific TT 6-4 PP (underlined) that was generated as previously described [17]. It was extended to a 53-mer oligonucleotide by ligating to its 5' end the 21-mer 5'-ACCGCAACGAAAGTGATTCCTC-3', and to its 3' end the 21-mer 5'-GAGGCTACTTGAACCAGACCG-3', using as a scaffold the 33-mer 5'-AAGTAGCCTCCTCCAACCTGCGAGGAATCAC-3'. The resulting 53-mer was separated from the scaffold and excess 21-mer on a 12% denaturing polyacrylamide gel containing 8 M urea, and used to construct the gap-lesion plasmid GP-TT-6-4 PP.

### 2.4. In vivo TLS assay

The TLS assay has been previously described [18–20]. Briefly, cells were co-transfected with a DNA mixture containing 100 ng of a gapped-lesion plasmid (GP-TT-CPD, or GP-TT-6-4 PP;  $\text{kan}^R$ ), 100 ng of a control gapped plasmid without a lesion (GP20;  $\text{cm}^R$ ), and 5  $\mu\text{g}$  of the carrier plasmid pUC18, using jetPEI/DNA complexes for the human fibroblast cells or the Nucleofector™ system (Amaxa, GmbH, Köln, Germany), for the BL2 cell lines. The cells were incubated 24 h in order to allow repair, and then the DNA was extracted using alkaline lysis conditions and used to transform *E. coli* reporter strains. The percentage of plasmid repair, of which most occurs by TLS, was calculated by dividing the number of transformants obtained from the gap-lesion plasmid (number of  $\text{kan}^R$  colonies) by the number of transformants obtained from the control gapped-plasmid (number of  $\text{cm}^R$  colonies). A small fraction of gap-lesion plasmids can be repaired by non-TLS events, which involve most likely formation of a double stranded break as an intermediate. These are observed as plasmid isolates with large deletions or insertions. To obtain precise TLS extents, the plasmid repair extents were multiplied by the fraction of TLS events out of all plasmid repair events, as obtained by DNA sequence analysis. To determine the DNA sequence changes that have occurred during plasmid repair, sequence analysis was carried using the Tem-

pliPhi DNA Sequencing Template Amplification Kit from GE Healthcare and the BigDye Terminator v1.1 Cycle Sequencing Kit from Applied Biosystems. Reactions were analyzed by capillary electrophoresis on an ABI PRISM™ 3130xl Genetic Analyzer from Applied Biosystems.


### 3. Results

#### 3.1. The experimental system

To analyze TLS across defined and site-specific UV lesions in a quantitative manner we used an assay system previously developed in our lab, based on transfection of cultured mammalian cells with gapped plasmids carrying site-specific lesions opposite the gap [18–21]. Briefly, the cells were transiently transfected with a mixture of a gap-lesion plasmid (kan<sup>R</sup>) carrying the site-specific UV lesion, a control gapped plasmid without the lesion (cm<sup>R</sup>), and a carrier plasmid (amp<sup>R</sup>). After allowing time for gap repair in the mammalian cells, the plasmids were extracted under alkaline conditions, such that only plasmids that have been completely filled in and ligated remained intact. These were used to transform *E. coli recA* cells, which were plated in parallel on LB-kanamycin plates to select for filled in gap-lesion plasmids, and LB-chloramphenicol plates to select for filled in control plasmids. The ratio of kan<sup>R</sup>/cm<sup>R</sup> colonies is an indication of the extent of TLS in the mammalian cells. Plasmids were extracted from kan<sup>R</sup> cells, and the DNA sequence was determined across the original damage site to reveal any sequence changes caused during gap filling. The plasmids do not replicate in the mammalian cells, enabling quantification of the extent of gap filling, but meaning that TLS was assayed uncoupled from replication and in the context of a plasmid. Studies previously performed in our lab have shown that this assay system is useful for studying TLS: it is affected by the cellular composition of DNA polymerases, and is subjected to at least some of the regulatory mechanisms controlling chromosomal TLS [18–21].

#### 3.2. TLS across a TT CPD is reduced in cells lacking *polη*

TLS was assayed using a gapped plasmid with a site-specific TT CPD in three pairs of *polη*-proficient and *polη*-deficient human cell types: primary fibroblasts from a normal individual and from an XPV patient, SV40-transformed fibroblasts from a normal individual and from an XPV patient, and Burkitt lymphoma cell line BL2 and its *polη*-deficient derivative. As can be seen in Fig. 1A and Table 1, the extent of TLS across the TT CPD in *polη*-proficient primary fibroblasts was 35%, compared to 8% in primary fibroblasts obtained from an XPV patient, representing a 4.4-fold decrease in the extent of TLS in the absence of *polη*. In SV40-transformed *polη*-proficient fibroblasts TLS across the TT CPD was high, reaching 81%, compared to 31% in SV40-transformed fibroblasts obtained from an XPV patient (Fig. 1A and Table 1), representing a 2.6-fold decrease in TLS in the absence of *polη*. TLS extents in the lymphoma cell lines were 19% and 7% for the *polη*-proficient and *polη*-deficient cells, respectively (Fig. 1A and Table 1), rep-



**Fig. 1 – TLS across a TT CPD in *polη*-proficient and *polη*-deficient cells. (A) The efficiency of TLS. (B) The error frequency of TLS. (C) The frequency of non-TLS events consisting of large deletions and insertions of sequences from the control plasmid. The data for the graph in panel A was taken from Table 1, and for the graphs presented in panels B and C from Tables 2 and 3.**

resenting a 2.7-fold lower TLS in the absence of *polη*. Thus, despite the presence of multiple additional DNA polymerases in the human cells, the absence of *polη* caused a significant deficiency in the ability to perform TLS across a TT CPD. The smaller effects in the SV40-transformed fibroblasts and the BL2 lymphoma cells may be due to deregulation of TLS, allowing ‘unauthorized’ DNA polymerases to perform TLS across the TT CPD, which is usually bypassed by *polη*.

#### 3.3. TLS across a TT CPD is much more mutagenic in cells lacking *polη*

To examine the fidelity and mutation types produced during TLS across the TT CPD we extracted kan<sup>R</sup> colonies from the TLS experiments described above, and subjected them to DNA sequence analysis. As can be seen in Tables 2 and 3 and Fig. 1B, the vast majority of gap filling events in primary fibroblasts

**Table 1 – TLS across a site-specific TT CPD in pol $\eta$ -proficient and pol $\eta$ -deficient human cells**

Cell type		Transformants		Plasmid repair (%)	TLS (%)
		Kan <sup>R</sup>	Cm <sup>R</sup>		
Primary fibroblasts	POLH <sup>+/+</sup>	121	357	35 ± 3	35 ± 3
	POLH <sup>-/-</sup> (XPV)	100	1066	9 ± 1	8 ± 1
SV40-transformed fibroblasts	POLH <sup>+/+</sup>	307	345	85 ± 5	81 ± 5
	POLH <sup>-/-</sup> (XPV)	523	1707	32 ± 3	31 ± 2
Burkitt's lymphoma cells	POLH <sup>+/+</sup>	223	1045	21 ± 2	19 ± 1
	POLH <sup>-/-</sup>	105	972	10 ± 2	7 ± 2

Plasmid mixtures containing GP-TT-CPD (kan<sup>R</sup>) along with the control GP20 (cm<sup>R</sup>) and the carrier plasmids were introduced into the indicated human cells, after which the DNA was extracted and introduced into an *E. coli* indicator strain. The extent of plasmid repair was calculated by the kan<sup>R</sup>/cm<sup>R</sup> ratio, and the extent of TLS was obtained by calculating this value by the percentage of TLS events out of all repair events, as determined by DNA sequence analysis, and shown in Tables 2 and 3. The colony counts are of a representative experiment. The efficiencies of plasmid repair and TLS were obtained by averaging the results of at least three experiments.

(78/79 events; 99%) are consistent with gap filling by TLS, and all (78/78) had the correct sequence AA inserted opposite the TT CPD. This represents an error frequency of <1.3%, which is consistent with the *in vitro* error frequency determined for purified human pol $\eta$  [22,23]. The picture was generally similar in the pol $\eta$ -proficient SV40-transformed fibroblasts and the BL2 lymphoma cell line, where accurate TLS accounted for 94% and 89%, respectively, however the fraction of mutagenic TLS was slightly higher (Tables 2 and 3, Fig. 1B). The accuracy of TLS across the TT CPD significantly changed in primary fibroblasts from XPV patients, where the fraction of errors made by TLS increased by >11-fold (15% of all isolates;  $P=0.002$ ; Table 3 and Fig. 1B). Large increases in mutagenic TLS at the CPD were also observed in SV40-transformed fibroblasts from XPV patients, and in the BL2 pol $\eta$ -deficient lymphoma cell line, reaching error frequencies 16-fold ( $P=0.0003$ ) and 6.4-fold ( $P=0.003$ ) higher, respectively, than in their cognate

pol $\eta$ -proficient cells (Table 3 and Fig. 1B). Thus, in the absence of pol $\eta$ , TLS across the TT CPD becomes more mutagenic by approximately an order of magnitude.

### 3.4. Mutagenic signature of TLS across a TT CPD in XPV cells

Generally the mutational patterns were similar in each of the three pol $\eta$ -deficient cell types (Tables 2 and 3). First, somewhat unexpectedly, a significant fraction of 23% of all the mutants (9/39) were semi-targeted, appearing not opposite the site of the CPD, but at its nearest flanking nucleotides (roughly equally distributed between the template nucleotides 3' and 5' to the CPD; Tables 2 and 3). Second, nearly all targeted mutations occurred opposite the 3' T of the CPD (the first to be encountered by the replicating polymerase). This included 97% (29/30) of the targeted mutations, which

**Table 2 – DNA sequence analysis of descendants of a gap-lesion plasmid carrying a site-specific TT CPD after repair in pol $\eta$ -proficient and pol $\eta$ -deficient human cells**

DNA sequence opposite TT CPD	Primary fibroblasts		SV40-transformed fibroblasts		Burkitt's lymphoma	
	POLH <sup>+/+</sup> <sup>a</sup>	POLH <sup>-/-</sup> <sup>a</sup>	POLH <sup>+/+</sup> <sup>a</sup>	POLH <sup>-/-</sup> <sup>a</sup>	POLH <sup>+/+</sup> <sup>a</sup>	POLH <sup>-/-</sup> <sup>a</sup>
C-AA-C	78 (99)	54 (78)	84 (94)	73 (81)	64 (89)	44 (56)
A-AA-C	-	2 (3)	-	1 (1)	1 (1.5)	-
G-AA-C	-	1 (1)	-	1 (1)	-	-
C-CA-C	-	-	-	1 (1)	-	-
C-GA-C	-	3 (4)	-	5 (6)	-	6 (8)
C-TA-C	-	2 (3)	-	5 (6)	-	7 (9)
C-AA-A	-	2 (3)	-	1 (1)	-	1 (1)
$\Delta$ -AA-C	-	-	1 (1)	-	-	-
C-AT-A	-	-	-	1 (1)	-	-
C-TA-A	-	-	-	-	1 (1.5)	-
Non-TLS events	1 (1)	5 (7)	4 (4)	2 (2)	6 (8)	20 (26)
Total	79 (100)	69 (100)	89 (100)	90 (100)	72 (100)	78 (100)

Plasmids were extracted from kan<sup>R</sup> colonies obtained in the experiments described in Table 1, and subjected to DNA sequence analysis. The sequence opposite the site of the TT CPD is shown in the 5'–3' direction. Accurate TLS is represented by the sequence 5'-CAAC-3'. The underlined nucleotides are those located opposite the original TT CPD. Mutations are presented by bold type.  $\Delta$  represents a single-nucleotide deletion. Non-TLS events include big deletions and insertion of sequences from the control plasmid.

<sup>a</sup> Number of isolates (%).

**Table 3 – Categories of molecular events occurring during TLS across a TT CPD in *polη*-proficient and *polη*-deficient human cells**

Cell type	Primary fibroblasts		SV40-transformed fibroblasts		Burkitt's lymphoma cells	
	POLH <sup>+/+</sup> <sup>a</sup>	POLH <sup>-/-</sup> <sup>a</sup>	POLH <sup>+/+</sup> <sup>a</sup>	POLH <sup>-/-</sup> <sup>a</sup>	POLH <sup>+/+</sup> <sup>a</sup>	POLH <sup>-/-</sup> <sup>a</sup>
Error-free TLS	78 (99)	54 (78)	84 (94)	73 (81)	64 (89)	44 (56)
Error-prone TLS	0 (<1)	10 (15) P=0.002	1 (1)	15 (17) P=0.0003	2 (3)	14 (18) P=0.003
Targeted mutations						
Transitions at 3' T		3		5		6
Transversions at 3' T		2		6		7
Small deletions			1			
Semi-targeted mutations						
3' to the lesion		3		2	1	
5' to the lesion		2		1		1
Tandem double				1		
Non-tandem double					1	
Non-TLS events (insertions or deletions)	1 (1)	5 (7) P=0.06	4 (4)	2 (2) P=0.4	6 (8)	20 (26) P=0.005
Total	79 (100)	69 (100)	89 (100)	90 (100)	72 (100)	78 (100)

Based on the data presented in Table 2. The statistical significance of the difference in mutant frequencies between pairs of POLH<sup>+/+</sup> and POLH<sup>-/-</sup> cells was calculated using the  $\chi^2$ -test, and the P values are presented.

<sup>a</sup> Number of isolates (%).

comprise 74% (29/39) of all mutagenic TLS events. One occurrence was a tandem double base substitution, which included the 5' T of the CPD, and the template G 5' to it.

### 3.5. Non-TLS events are increased at a TT CPD in cells lacking *polη*

Some of the DNA sequences obtained contained deletions and insertions at the original gap-lesion site in the plasmid, which were clearly the result of non-TLS events. The deletions were typically 9–70-bp long, and the insertions were typically 5–50-bp long, originating from the control plasmid GP20. They represent, most likely, events initiated by breakage of the plasmid at the ssDNA region, creating effectively a double strand break (DSB). Such DSB can be repaired by non-homologous

end joining (NHEJ) or homologous recombination (HR), as previously shown ([1,24] and Covo and Livneh, in preparation). The non-TLS events are infrequent in normal fibroblasts (1/79; 1.3%), however they increased by approximately fivefold (5/69; 7%; P=0.06) in primary fibroblasts from XPV patients (Table 3 and Fig. 1C). Similarly, a significant fraction of DSB-related events were observed in BL2 *polη*-deficient cells, amounting to 26% (20/78) of all isolates, which was 3-fold higher than in the parental BL2 *polη*-proficient cell line (Table 3 and Fig. 1C). In the SV40-transformed fibroblast cell lines the fraction of DSB-related events was similar with and without *polη*, but the numbers of events were too small to draw firm conclusions. The increase in the putative DSB-related events observed in cells lacking *polη* is consistent with strand breakage caused by a difficulty in synthesizing across the CPD due to the deficiency in TLS.

**Table 4 – TLS across a site-specific TT 6-4 PP in *polη*-proficient and *polη*-deficient human cells**

Cell type		Transformants		Plasmid repair (%)	TLS (%)
		Kan <sup>R</sup>	Cm <sup>R</sup>		
Primary fibroblasts	POLH <sup>+/+</sup>	323	2064	14 ± 3	13 ± 3
	POLH <sup>-/-</sup> (XPV)	274	2207	12 ± 2	11 ± 2
SV-40 transformed fibroblasts	POLH <sup>+/+</sup>	154	332	41 ± 4	40 ± 4
	POLH <sup>-/-</sup> (XPV)	342	1022	29 ± 2	28 ± 2
Burkitt's lymphoma cells	POLH <sup>+/+</sup>	88	566	15 ± 2	14 ± 1
	POLH <sup>-/-</sup>	68	790	8 ± 1	7 ± 1

The experiments were performed as described in the legend to Table 1, except that the gap-lesion plasmid was GP-TT-6-4-PP (kan<sup>R</sup>). The extent of plasmid repair was calculated by the kan<sup>R</sup>/cm<sup>R</sup> ratio, and the extent of TLS was obtained by multiplying this value by the percentage of TLS events out of all repair events, as determined by DNA sequence analysis, and shown in Tables 5 and 6. The colony counts are of a representative experiment. The efficiencies of plasmid repair and TLS were obtained by averaging the results of at least three experiments.

**Table 5 – DNA sequence analysis of descendants of a gap-lesion plasmid carrying a site-specific TT 6-4 PP after repair in pol $\eta$ -proficient and pol $\eta$ -deficient human cells**

DNA sequence opposite TT 6-4 PP	Primary fibroblasts		SV40-transformed fibroblasts		Burkitt's lymphoma cells	
	POLH <sup>+/+a</sup>	POLH <sup>-/-a</sup>	POLH <sup>+/+a</sup>	POLH <sup>-/-a</sup>	POLH <sup>+/+a</sup>	POLH <sup>-/-a</sup>
C-AA-C	59 (46)	40 (40)	43 (47)	22 (34)	86 (68)	54 (55)
A-AA-C	–	–	1 (1)	–	2 (2)	–
T-AA-C	1 (1)	1 (1)	7 (8)	1 (2)	–	–
C-CA-C	1 (1)	–	1 (1)	2 (3)	–	1 (1)
C-GA-C	5 (4)	5 (5)	2 (2)	2 (3)	2 (2)	1 (1)
C-TA-C	2 (2)	3 (3)	1 (1)	2 (3)	–	2 (2)
C-AC-C	2 (2)	1 (1)	3 (3)	2 (3)	1 (1)	–
C-AG-C	3 (2)	–	–	2 (3)	3 (2)	1 (1)
C-AT-C	3 (2)	–	3 (3)	1 (2)	1 (1)	1 (1)
C-AA-A	25 (20)	32 (32)	22 (24)	17 (27)	11 (9)	15 (15)
C-AA-G	–	1 (1)	–	–	–	–
C-AA-T	–	–	–	1 (2)	–	1 (1)
C-AA-C	–	–	4 (4)	1 (2)	1 (1)	3 (3)
C-AA-C	1 (1)	–	–	–	5 (4)	8 (8)
C-AA-Δ	–	–	–	1 (2)	–	–
C-AA-Δ	–	–	–	–	–	1 (1)
A-CA-C	–	1 (1)	–	–	–	–
A-GA-C	–	–	–	1 (2)	–	–
A-TA-C	1 (1)	–	–	–	–	–
T-CA-C	1 (1)	–	–	–	–	–
C-CC-C	–	1 (1)	–	–	–	–
C-GC-C	1 (1)	–	–	–	–	–
C-TG-C	1 (1)	–	–	–	1 (1)	–
C-TT-C	–	2 (2)	–	1 (2)	1 (1)	1 (1)
A-AG-C	–	–	1 (1)	–	–	–
C-GA-A	3 (2)	2 (2)	–	4 (6)	4 (3)	2 (2)
C-TA-A	7 (5)	–	–	2 (3)	2 (2)	–
Non-TLS events	12 (9)	10 (10)	3 (3)	2 (3)	6 (5)	8 (8)
Total	128 (100)	99 (100)	91 (100)	64 (100)	126 (100)	99 (100)

Plasmids were extracted from kan<sup>R</sup> colonies obtained in the experiments described in Table 4, and subjected to DNA sequence analysis. The sequence opposite the site of the TT 6-4 PP is shown in the 5'–3' direction. Accurate TLS is represented by the sequence 5'-CAAC-3'. The underlined nucleotides are those located opposite the original TT 6-4 PP. Mutations are presented by bold type. Δ represents a one-nucleotide deletion. Non-TLS events include big deletions and insertion of sequences from the control plasmid.

<sup>a</sup> Number of isolates (%).


### 3.6. TLS across a site-specific TT 6-4 PP is marginally affected by the lack of pol $\eta$

In order to examine TLS across a TT 6-4 PP we performed a similar set of TLS experiments with a gapped plasmid carrying a site-specific TT 6-4 PP in the three pairs of pol $\eta$ -proficient and pol $\eta$ -deficient cell types. As can be seen in Fig. 2A and Table 4, the extent of TLS across the TT 6-4 PP in primary fibroblasts was lower than across TT CPD, suggesting that the TLS machinery copes less well with this type of lesion, perhaps due to the larger deformation that it causes in DNA, and the lack of a specific DNA polymerase which is able to bypass it. When assayed in primary fibroblasts from XPV patients, TLS across TT 6-4 PP was the same as in primary fibroblasts from normal individuals (Fig. 2A and Table 4), suggesting that pol $\eta$  does not play a significant role in TLS across this lesion. In the pair of SV40-transformed fibroblasts the extent of TLS across this lesion was higher than in primary fibroblasts, and there appears to be a slight decrease in TLS in the XPV cell line compared to the pol $\eta$ -proficient line (Fig. 2A and Table 4). Interestingly, in the BL2 pol $\eta$ -deficient cell line, TLS across the

TT 6-4 PP was nearly twofold lower than in its pol $\eta$ -proficient parental cell line (Fig. 2A and Table 4). This might be significant, since unlike the previous cell type pairs, this pair of cells is isogenic. Thus, it is possible that at least under some conditions, perhaps when TLS is deregulated, pol $\eta$  might be involved in bypass across a TT 6-4 PP.

### 3.7. TLS across TT 6-4 PP is highly mutagenic, with a complex spectrum that is unaffected by the absence of pol $\eta$

To establish the type of mutations formed during TLS across a TT 6-4 PP, we performed DNA sequence analysis of plasmids isolated from kan<sup>R</sup> colonies obtained in TLS experiments with gapped plasmid carrying the site-specific TT 6-4 PP. As can be seen in Fig. 2B and Tables 5 and 6, TLS across the TT 6-4 PP was highly mutagenic in primary fibroblasts, with 45% (57/128) of the bypass products carrying point mutations. Very similar results were obtained with primary fibroblasts from XPV patients. Also in the two other cell pairs TLS across the TT 6-4 PP was highly mutagenic, with no significant difference between cells with or without pol $\eta$  (Fig. 2B and Tables 5 and 6).



**Fig. 2 – TLS across a TT 6-4 PP in *polη*-proficient and *polη*-deficient cells. (A) The efficiency of TLS. (B) The error frequency of TLS. (C) The frequency of non-TLS events consisting of large deletions and insertions of sequences from the control plasmid. The data for the graph in panel A was taken from Table 4, and for the graphs presented in panels B and C from Tables 5 and 6.**

The DNA sequence changes caused by TLS across the TT 6-4 PP exhibited a large variety of mutations, with no significant difference between cells with or without *polη* (Tables 5 and 6). Notably, the most abundant mutation was a G → T transversion semi-targeted to the template G located 5' to the TT 6-4 PP. It accounted for 44% (25/57) of the mutations in primary normal fibroblasts, with similar abundance in the other cell types. Targeted base substitutions were formed opposite each of the two T bases of the TT 6-4 PP, and small but significant fractions of tandem and no-tandem double base substitutions, and minus 1 deletions, were observed (Tables 5 and 6).

#### 4. Discussion

The involvement of *polη* in the relatively error-free TLS across UV lesions, specifically CPD, is well established [5,6,23]. Still previous studies have not measured in a direct and quantitative fashion the effect of the absence of *polη* on TLS across defined UV lesions. In order to ensure that effects

observed in cells lacking *polη* were indeed due to the absence of this polymerase, we performed our study in three pairs of *polη*-proficient and *polη*-deficient human cells. As cell lines frequently accumulate genetic changes that might affect a variety of normal pathways, of the cells used, primary fibroblasts are perhaps the closest to the definition of a normal cell. Primary fibroblasts lacking *polη* that were obtained from an XPV patient, obviously originated from a different person, and thus were not isogenic to the control normal fibroblasts. Likewise, the second pair of SV40-transformed fibroblasts is not isogenic. In contrast, the third pair was isogenic: the cell line BL2, derived from a Burkitt lymphoma patient, and a *polη*-knockout derivative of it. The fact that in all 3 cell-pairs TLS across the TT CPD in the *polη*-deficient cell was less efficient and more mutagenic than in its cognate *polη*-proficient cell indicates that these effects are indeed mainly due to the lack of *polη*.

There was a variation among the three *polη*-proficient cell types in the extent of TLS across the TT CPD, varying from 21% to 85%. A similar variation, from 15% to 41% was observed for

**Table 6 – Categories of molecular events occurring during TLS across a TT 6-4 PP in pol $\eta$ -proficient and pol $\eta$ -deficient human cells**

Cell type	Primary fibroblasts		SV40-transformed fibroblasts		Burkitt's lymphoma cells	
	POLH <sup>+/+a</sup>	POLH <sup>-/-a</sup>	POLH <sup>+/+a</sup>	POLH <sup>-/-</sup>	POLH <sup>+/+a</sup>	POLH <sup>-/-a</sup>
Error-free TLS	59 (46)	40 (40)	43 (47)	22 (34)	86 (68)	54 (55)
Error-prone TLS	57 (45)	49 (50)	45 (50)	40 (63)	34 (27)	37 (37)
Targeted mutations						
Transitions						
At 3' T	5	5	2	2	2	1
At 5' T	3			2	3	1
Transversions						
At 3' T	3	3	2	4		3
At 5' T	5	1	6	3	2	1
Small deletions	1		4	2	6	12
Semi-targeted mutations						
3' to the lesion	1	1	8	1	2	
5' to the lesion	25	33	22	18	11	16
Tandem double	4	4		2	2	1
Non-tandem double	10	2	1	6	6	2
Non-TLS events (insertions or deletions)	12 (9)	10 (10)	3 (3)	2 (3)	6 (5)	8 (8)
Total	128 (100)	99 (100)	91 (100)	64 (100)	126 (100)	99 (100)

Based on the data presented in Table 5.

<sup>a</sup> Number of isolates (%).

TLS across the TT 6-4 PP. The reasons for these variations are not clear, but they may stem, at least in part from differences in the regulation or performance of the TLS machinery. For example, the higher TLS in SV40-transformed fibroblasts, in which p53 is inactivated [25], is consistent with the finding that p53 suppresses TLS [20]. This correlation does not hold for the BL2 cell lines, which overexpress Mdm2, thereby causing a deficiency in p53 [26]. In any case, for all three cell-pairs, TLS across TT CPD was lower in the pol $\eta$ -deficient cell compared to its pol $\eta$ -proficient control by 2.6–4.4-fold. Thus, despite the presence of a multiplicity of other DNA polymerases in the cell, the lack of pol $\eta$  is not fully compensated by other TLS polymerases as far as efficiency of TLS is concerned.

When the accuracy of TLS across the TT CPD is considered, in all three cell-pairs there was a dramatic increase of about an order of magnitude in the mutagenicity of TLS across a TT CPD in cells lacking pol $\eta$  compared to their pol $\eta$ -proficient counterparts. Examination of the mutations caused by the TT CPD in cells lacking pol $\eta$  revealed nearly equal numbers of transversions and transitions, most of which were targeted to the 3' T of the TT CPD. Most interestingly, nearly a quarter of the mutations were semi-targeted to the two nearest nucleotides flanking the TT CPD. To our knowledge, this is the first demonstration that TLS across a defined TT CPD is much more mutagenic in mammalian cells lacking pol $\eta$  in general, and cells from XPV patients in particular, and the first report on the specificity of its mutagenicity.

The mutagenic spectrum of the 6-4 adducts is complex, and includes nearly every possible point mutation opposite the 6-4 PP, and the two nearest bases flanking it. This highlights the

significant structural deviation of this lesion from the structure of two adjacent normal T bases, and the difficulty of fitting a particular base in the active site of the polymerase performing the insertion opposite the lesion. It is therefore remarkable that in 35–59% of the TLS events the correct AA nucleotides are inserted opposite the TT 6-4 PP. However, this might not represent the ability of the TLS system to correctly pair the dAMP residues opposite the TT 6-4 PP, but rather a fortuitous insertion according to the 'A rule', whereby an A is preferentially inserted opposite non-coding lesions such as an abasic site [18,27,28] or a  $-(CH_2)_3$ -insert [21]. The hotspot of the semi-targeted G  $\rightarrow$  T transversion at the template G located 5' to the TT 6-4 PP may be another manifestation of the local deformation caused by the 6-4 PP, which affects the base pairing at neighboring template base, as are the tandem double and non-tandem double point mutations in this site.

Previous studies have used site-specific TT CPD and TT 6-4 PP in various forms of vectors in mammalian cells, however, as the assays in those studies were not quantitative, the efficiency of TLS could not be estimated [29,30]. As far as mutational specificity is concerned, the mutational spectrum of a TT CPD was previously not determined in XPV cells. In contrast, the mutability of a TT 6-4 PP was determined in monkey cells, using a replicating plasmid [29,30]. Our results are comparable to those obtained in the COS cells, including the semi-targeted hot spot. Interestingly, while we found essentially no difference in insertion specificity opposite TT 6-4 PP in human cells with or without pol $\eta$ , the situation in *S. cerevisiae* might be different. Thus, it was reported that in this organism mutagenic TLS across TT 6-4 PP was strongly suppressed

in a *rad30Δ* strain lacking *polη* [31]. A second study, using a different sequence context around the lesion, found only a very small difference [32]. These differences may reflect differences in DNA sequence context, or a difference between humans and *S. cerevisiae* in the DNA polymerases involved in TLS across TT 6-4 PP, reflecting perhaps the fact that the former have more TLS polymerases [33].

Several studies suggested that CPD rather than 6-4 PP are the main premutagenic lesions, perhaps because 6-4 PP are both less abundant, and repaired much better than CPD [34–37]. However, the identity of the polymerase that causes CPD-induced mutations in wild-type cells is not clear. The main candidate is *polη*, since it is responsible for the majority of TLS across CPD in human cells [38]. Most UV-induced mutations occur at cytosines, suggesting involvement of cytosine-containing CPD. The latter have been shown to undergo facilitated spontaneous deamination, which converts them into U-containing CPD, i.e., UT, TU and UU [39,40] which exhibit coding properties similar to TT CPD [41,42]. Thus, the combination of spontaneous deamination of C-containing CPD, followed by bypass of the resultant U-containing CPD by *polη* provides a potent mutagenic pathway for UV-induced C → T transitions. It has been estimated that C-containing CPD in DNA deaminate in vitro with a half-life of approximately 5 h [40]. Thus, the contribution of this process to UV mutagenesis might be significant, depending on the in vivo rates of deamination on one hand, and TLS on the other hand. In any case, it should be kept in mind that other polymerases can substitute for *polη* in bypass across CPD, and with a much higher error frequency as shown above, a process that might also contribute to the mutagenesis of UV.

Analysis of UV mutations in the HPRT gene in human cells showed that 33% and 42% occurred at a template T, in normal and XPV fibroblasts, respectively, for which the results obtained with the TT CPD are directly relevant [43]. In that study one of the main differences in the UV mutational spectra of normal and XPV cells, was a strong increase in the occurrence of transversions at the expense of transitions in the latter. Thus, in XPV cells 62% of the mutations were transversions, whereas in normal cells they accounted to only 14%. When mutations at only T are concerned, the frequency was 58% transversions versus 14%, respectively [43]. Similar results were obtained also in assay systems based on shuttle vectors [44]. Our results presented above showed that in XPV cells 52% (15/29) of the base substitutions targeted to the lesions were transversions, and the majority of those were T → A, which may explain the occurrence of this mutation in about 50% of the transversions at AT pairs in the HPRT system.

Failure to bypass DNA lesions may lead to the formation of DSB, and subsequent deletions and chromosomal abnormalities. In particular, it was shown that in XPV cells, UV light, which does not directly form DSB in DNA, caused the appearance of DSB, presumably due to the inability to replicate across UV lesions, which may be responsible, at least in part, for the UV sensitivity of these cells [45,46]. Interestingly, although the gapped plasmid system does not involve replication, we have observed that when the TT CPD-containing gapped plasmid was analyzed in cells lacking *polη*, the fraction of non-TLS events consisting of large deletions and insertions signifi-

cantly increased. The simplest explanation for these events is the formation of a break in the ssDNA region of the plasmid due to failure of TLS. This is practically a DSB in the plasmid, and it may be repaired by either NHEJ, with the accompanying formation of deletions, or homologous recombination repair with the control intact plasmid [47,48]. This effect appears to be specifically the result of failure to bypass the TT CPD, since it was not observed for the TT 6-4 PP lesions, in which there was no difference in the frequency of deletions/insertions events between *polη*-proficient and deficient cells.

The skin cancer predisposition of XPV patients is explained by a germ-line mutation in the *POLH* gene that renders them *polη*-deficient, combined with the exposure to sunlight that produces DNA lesions, leading to increased mutagenesis and therefore facilitated carcinogenesis. Indeed, it has long been known that cells from XPV patients exhibit UV sensitivity and hyper-mutability [1]. The identification of CPD as the major mutagenic UV lesion, along with the ability of purified *polη*, which is lacking in XPV patients, to efficiently and relatively accurately bypass CPD, led to the explanation that much of the phenotypes of XPV cells can be explained by a deficiency in TLS across CPD [1]. The results presented here provide direct evidence that supports this explanation, by demonstrating that TLS across a TT CPD in the absence of *polη* is less efficient, and much more mutagenic.

---

### Conflict of interest statement

None.

---

### Acknowledgements

We thank A. Lehmann (Falmer, Brighton, UK) for the MRC5 and XP3ORO cells. This work was supported by grants to ZL from the Flight Attendant Medical Research Institute, Florida, USA, the Israel Science Foundation (no. 564/04), and the M.D. Moross Institute for Cancer Research, Weizmann Institute of Science. We thank Dr. A. Kolbanovskiy for the synthesis of some of the TT CPD & TT 6-4 PP lesions, work supported by NIH/NCI Grant CA099194 at New York University. We thank Dr. T. Paz-Elizur and S. Shachar for their help in developing high-throughput DNA sequence analysis.

---

### REFERENCES

- [1] E.C. Friedberg, G.C. Walker, W. Siede, R.D. Wood, R.A. Schultz, T. Ellenberger, *DNA Repair and Mutagenesis*, ASM Press, Washington, DC, 2006.
- [2] M.P. Vreeswijk, A. van Hoffen, B.E. Westland, H. Vrieling, A.A. van Zeeland, L.H. Mullenders, Analysis of repair of cyclobutane pyrimidine dimers and pyrimidine 6-4 pyrimidone photoproducts in transcriptionally active and inactive genes in Chinese hamster cells, *J. Biol. Chem.* 269 (1994) 31858–31863.
- [3] B.S. Tung, W.G. McGregor, Y.C. Wang, V.M. Maher, J.J. McCormick, Comparison of the rate of excision of major UV photoproducts in the human HPRT gene of normal and xeroderma pigmentosum variant cells, *Mutat. Res.* 362 (1996) 65–74.

- [4] S. Nakajima, L. Lan, S. Kanno, M. Takao, K. Yamamoto, A.P. Eker, A. Yasui, UV light-induced DNA damage and tolerance for the survival of nucleotide excision repair-deficient human cells, *J. Biol. Chem.* 279 (2004) 46674–46677.
- [5] R.E. Johnson, S. Prakash, L. Prakash, Efficient bypass of a thymine–thymine dimer by yeast DNA polymerase, *Pol eta*, *Science* 283 (1999) 1001–1004.
- [6] C. Masutani, R. Kusumoto, A. Yamada, N. Dohmae, M. Yokoi, M. Yuasa, M. Araki, S. Iwai, K. Takio, F. Hanaoka, The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta, *Nature* 399 (1999) 700–704.
- [7] V.M. Maher, L.M. Ouellette, R.D. Curren, J.J. McCormick, Frequency of ultraviolet light-induced mutations is higher in xeroderma pigmentosum variant cells than in normal human cells, *Nature* 261 (1976) 593–595.
- [8] J.H. Hoeijmakers, Genome maintenance mechanisms for preventing cancer, *Nature* 411 (2001) 366–374.
- [9] T. Ohkumo, Y. Kondo, M. Yokoi, T. Tsukamoto, A. Yamada, T. Sugimoto, R. Kanao, Y. Higashi, H. Kondoh, M. Tatematsu, C. Masutani, F. Hanaoka, UV-B radiation induces epithelial tumors in mice lacking DNA polymerase eta and mesenchymal tumors in mice deficient for DNA polymerase iota, *Mol. Cell. Biol.* 26 (2006) 7696–7706.
- [10] C.A. Dumstorf, A.B. Clark, Q. Lin, G.E. Kissling, T. Yuan, R. Kucherlapati, W.G. McGregor, T.A. Kunkel, Participation of mouse DNA polymerase iota in strand-biased mutagenic bypass of UV photoproducts and suppression of skin cancer, *Proc. Natl. Acad. Sci. U.S.A.* 103 (2006) 18083–18088.
- [11] Y. Wang, R. Woodgate, T.P. McManus, S. Mead, J.J. McCormick, V.M. Maher, Evidence that in xeroderma pigmentosum variant cells, which lack DNA polymerase eta, DNA polymerase iota causes the very high frequency and unique spectrum of UV-induced mutations, *Cancer Res.* 67 (2007) 3018–3026.
- [12] A. Tissier, E.G. Frank, J.P. McDonald, S. Iwai, F. Hanaoka, R. Woodgate, Misinsertion and bypass of thymine–thymine dimers by human DNA polymerase iota, *EMBO J.* 19 (2000) 5259–5266.
- [13] Y. Zhang, F. Yuan, X. Wu, J.-S. Taylor, Z. Wang, Response of human DNA polymerase iota to DNA lesions, *Nucleic Acids Res.* 29 (2001) 928–935.
- [14] Q. Gueranger, A. Stary, S. Aoufouchi, A. Faili, A. Sarasin, C.A. Reynaud, J.C. Weill, Role of human DNA polymerases eta, iota, and zeta in UV resistance and UV-induced mutagenesis in a human cell line, *DNA Repair*, in press.
- [15] G. Tomer, Z. Livneh, Analysis of unassisted translesion replication by the DNA polymerase III holoenzyme, *Biochemistry* 38 (1999) 5948–5958.
- [16] S.K. Banerjee, R.B. Christensen, C.W. Lawrence, J.E. LeClerc, Frequency and spectrum of mutations produced by a single cis-syn thymine–thymine cyclobutane dimer in a single-stranded vector, *Proc. Natl. Acad. Sci. U.S.A.* 85 (1988) 8141–8145.
- [17] J.E. LeClerc, A. Borden, C.W. Lawrence, The thymine–thymine pyrimidine–pyrimidone(6-4) ultraviolet light photoproduct is highly mutagenic and specifically induces 3' thymine-to-cytosine transitions in *Escherichia coli*, *Proc. Natl. Acad. Sci. U.S.A.* 88 (1991) 9685–9689.
- [18] S. Avkin, S. Adar, G. Blander, Z. Livneh, Quantitative measurement of translesion replication in human cells: evidence for bypass of abasic sites by a replicative DNA polymerase, *Proc. Natl. Acad. Sci. U.S.A.* 99 (2002) 3764–3769.
- [19] S. Avkin, M. Goldsmith, S. Velasco-Miguel, N. Geacintov, E.C. Friedberg, Z. Livneh, Quantitative analysis of translesion DNA synthesis across a benzo[a]pyrene-guanine adduct in mammalian cells. The Role of DNA polymerase  $\kappa$ , *J. Biol. Chem.* 279 (2004) 53298–53305.
- [20] S. Avkin, Z. Sevilay, L. Toubé, N.E. Geacintov, S.G. Chaney, M. Oren, Z. Livneh, p53 and p21 regulate error-prone DNA repair to yield a lower mutation load, *Mol. Cell* 22 (2006) 407–413.
- [21] S. Adar, Z. Livneh, Translesion DNA synthesis across non-DNA segments in cultured human cells, *DNA Repair (Amst.)* 5 (2006) 479–490.
- [22] R.E. Johnson, M.T. Washington, S. Prakash, L. Prakash, Fidelity of human DNA polymerase eta, *J. Biol. Chem.* 275 (2000) 7447–7450.
- [23] S.D. McCulloch, R.J. Kokoska, C. Masutani, S. Iwai, F. Hanaoka, T.A. Kunkel, Preferential cis-syn thymine dimer bypass by DNA polymerase eta occurs with biased fidelity, *Nature* 428 (2004) 97–100.
- [24] K.K. Khanna, S.P. Jackson, DNA double-strand breaks: signaling, repair and the cancer connection, *Nat. Genet.* 27 (2001) 247–254.
- [25] T.M. Bryan, R.R. Reddel, SV40-induced immortalization of human cells, *Crit. Rev. Oncogen.* 5 (1994) 331–357.
- [26] C. Capoulade, B. Bressac-de Paillerets, I. Lefrère, M. Ronsin, J. Feunteun, T. Tursz, J. Wiels, Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells, *Oncogene* 16 (1998) 1603–1610.
- [27] L.A. Loeb, B.D. Preston, Mutagenesis by apurinic/aprimidinic sites, *Annu. Rev. Genet.* 20 (1986) 201–230.
- [28] B.S. Strauss, The 'A rule' of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions? *Bioessays* 13 (1991) 79–84.
- [29] A. Gentil, F. Le Page, A. Margot, C.W. Lawrence, A. Borden, A. Sarasin, Mutagenicity of a unique thymine–thymine dimer or thymine–thymine pyrimidine pyrimidone (6-4) photoproduct in mammalian cells, *Nucleic Acids Res.* 24 (1996) 1837–1840.
- [30] H. Kamiya, S. Iwai, H. Kasai, The (6-4) photoproduct of thymine–thymine induces targeted substitution mutations in mammalian cells, *Nucleic Acids Res.* 26 (1998) 2611–2617.
- [31] A. Bresson, R.P.P. Fuchs, Lesion bypass in yeast cells: Pol eta participates in a multi-DNA polymerase process, *EMBO J.* 21 (2002) 3881–3887.
- [32] P.E. Gibbs, J. McDonald, R. Woodgate, C.W. Lawrence, The relative roles in vivo of *Saccharomyces cerevisiae* Pol eta, Pol zeta, Rev1 protein and Pol32 in the bypass and mutation induction of an abasic site, T-T (6-4) photoadduct and T-T cis-syn cyclobutyl dimer, *Genetics* 169 (2005) 575–582.
- [33] H. Ohmori, E.C. Friedberg, R.P.P. Fuchs, M.F. Goodman, F. Hanaoka, D. Hinkle, T.A. Kunkel, C.W. Lawrence, Z. Livneh, T. Nohmi, L. Prakash, S. Prakash, T. Todo, G.C. Walker, Z. Wang, R. Woodgate, The Y-family of DNA polymerases, *Mol. Cell* 8 (2001) 7–8.
- [34] H. Asahina, Z.-B. Han, M. Kawanishi, T. Kato Jr., H. Ayaki, T. Todo, T. Yagi, H. Takebe, M. Ikenaga, S.H. Kimura, Expression of a mammalian DNA photolyase confers light-dependent repair activity and reduces mutations of UV-irradiated shuttle vectors in xeroderma pigmentosum cells, *Mutat. Res.* 435 (1999) 255–262.
- [35] Y.-H. You, D.-H. Lee, J.-H. Yoon, S. Nakajima, A. Yasui, G.P. Pfeifer, Cyclobutane pyrimidine dimers are responsible for the vast majority of mutations induced by UVB irradiation in mammalian cells, *J. Biol. Chem.* 276 (2001) 44688–44694.
- [36] G. Giglia-Mari, A. Sarasin, TP53 mutations in human skin cancers, *Hum. Mutat.* 21 (2003) 217–228.
- [37] G.P. Pfeifer, Y.-H. You, A. Besaratinia, Mutations induced by ultraviolet light, *Mutat. Res.* 571 (2005) 19–31.
- [38] A. Stary, P. Kannoche, A.R. Lehmann, A. Sarasin, Role of DNA polymerase eta in the UV mutation spectrum in human cells, *J. Biol. Chem.* 278 (2003) 18718, 18767–18775.

- [39] M. Ruiz-Rubio, R. Bockrath, On the possible role of cytosine deamination in delayed photoreversal mutagenesis targeted at thymine–cytosine dimers in *E. coli*, *Mutat. Res.* 210 (1989) 93–102.
- [40] Y. Barak, O. Cohen-Fix, Z. Livneh, Deamination of cytosine-containing pyrimidine photodimers in UV-irradiated DNA: significance for UV light mutagenesis, *J. Biol. Chem.* 270 (1995) 24174–24179.
- [41] N. Jiang, J.S. Taylor, In vivo evidence that UV-induced C→T mutations at dipyrimidine sites could result from the replicative bypass of cis-syn cyclobutane dimers or their deamination products, *Biochemistry* 32 (1993) 472–481.
- [42] K. Takasawa, C. Masutani, F. Hanaoka, S. Iwai, Chemical synthesis and translesion replication of a cis-syn cyclobutane thymine–uracil dimer, *Nucleic Acids Res.* 32 (2004) 1738–1745.
- [43] Y.C. Wang, V.M. Maher, D.L. Mitchell, J.J. McCormick, Evidence from mutation spectra that the UV hypermutability of xeroderma pigmentosum variant cells reflects abnormal, error-prone replication on a template containing photoproducts, *Mol. Cell. Biol.* 13 (1993) 4276–4283.
- [44] H.L. Waters, S. Seetharam, M.M. Seidman, K.H. Kraemer, Ultraviolet hypermutability of a shuttle vector propagated in xeroderma pigmentosum variant cells, *J. Invest. Dermatol.* 101 (1993) 744–748.
- [45] C.L. Limoli, E. Giedzinski, W.F. Morgan, J.E. Cleaver, Polymerase eta deficiency in the xeroderma pigmentosum variant uncovers an overlap between the S phase checkpoint and double-strand break repair, *Proc. Natl. Acad. Sci. U.S.A.* 97 (2000) 7039–7946.
- [46] S. Squires, J.A. Coates, M. Goldberg, L.H. Toji, S.P. Jackson, D.J. Clarke, R.T. Johnson, p53 prevents the accumulation of double-strand DNA breaks at stalled-replication forks induced by UV in human cells, *Cell Cycle* 3 (2004) 1543–1557.
- [47] M. van den Bosch, P.H. Lohman, A. Pastink, Double strand-break repair by homologous recombination, *Biol. Chem.* 383 (2002) 873–892.
- [48] S. Burma, B.P. Chen, D.J. Chen, Role of non-homologous end joining in maintaining genomic integrity, *DNA Repair* 5 (2006) 1042–1048.